# Sermorelin Research: GHRH(1-29) Mechanism, GH/IGF-1 Findings, and Safety > Sermorelin research summarized: the GHRH-receptor mechanism of action, GH and IGF-1 findings in children and older adults, side effects, and the analogue comparisons, cited. The mechanism at the receptor, the GH/IGF-1 findings in children and older adults, the side effects on record, and how the analogues differ — read straight from the published literature. ## The short version This is the long read on sermorelin research. Sermorelin tells the pituitary to release the body's own growth hormone, which then raises IGF-1 (a growth signal from the liver). In children who were not growing it sped up growth; in older men it pushed growth-hormone and IGF-1 numbers back toward young-adult levels for two weeks. Side effects in studies were mostly mild injection-site reactions. The flashier claims — fat loss, anti-aging, muscle — are weaker than the marketing suggests, and where there is strong body-composition data, it comes from a related analogue, tesamorelin, not from sermorelin itself. ## Sermorelin Mechanism of Action at the GHRH Receptor Sermorelin mechanism of action begins at the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on anterior-pituitary somatotrophs. Binding activates the Gs / adenylate cyclase / cAMP / protein kinase A (PKA) cascade — in plain terms, the receptor switches on a second messenger (cAMP) that switches on an enzyme (PKA), which drives GH gene transcription and the release of stored growth hormone [15]. GHRH(1-29) is the shortest fragment of the 44-residue hormone that retains this full activity — everything past residue 29 can be removed without losing potency at the receptor [15]. Because the signal is delivered upstream, the downstream consequences (a rise in hepatic IGF-1, and the somatostatin/IGF-1 feedback that follows) stay within the body's own feedback loop rather than overriding it [4]. A 2025 review in *Nature Reviews Endocrinology* synthesizes this GHRH-receptor biology and the broader GH/IGF-1 axis across health and disease [15]. ## Does sermorelin work? In the clearest adult dataset, GHRH(1-29) at 0.5 mg and 1 mg subcutaneous twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1 in healthy older men (mean 68 years); at the high dose, GH/IGF-1 parameters no longer differed from those of young men, with no change in fasting glucose [2]. In prepubertal GH-deficient children, once-daily dosing raised first-year height velocity from ~4.1 to ~7-8 cm/year [1]. The honest caveat: these are GH-axis endpoints, and authorities caution that secretagogue use for aging is not yet established [5]. ## Sermorelin Benefits Studied in the GH/IGF-1 Axis The sermorelin benefits that hold up in the literature are GH-axis benefits, measured as hormone changes rather than promised outcomes. The anchor finding: in healthy older men, twice-daily GHRH(1-29) for 14 days reversed the age-related decline in GH and IGF-1, returning the high-dose group to young-adult levels [2]. The 2025 *Nature Reviews Endocrinology* review frames GHRH agonists as a class with applications across the GH/IGF-1 axis [15]. For the brain, the strongest controlled signal comes from the GHRH class rather than sermorelin specifically. In a randomized, double-blind, placebo-controlled trial of 152 older adults — 66 of them with mild cognitive impairment — 20 weeks of a daily GHRH analogue had a favorable effect on cognition (P=0.03), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% [6]. That trial used the stabilized analogue tesamorelin; it is GHRH-axis evidence, read here as drug-class context, not a sermorelin-specific result. ## Sermorelin Before and After: What the Studies Actually Measured "Sermorelin before and after" online usually means photographs. In the literature it means endpoints. The pediatric before/after is a height-velocity change — from about 4.1 cm/year to roughly 7-8 cm/year in the first year of once-daily therapy, without excessive IGF-1 generation [1]. The adult before/after is a 24-hour hormone profile — dose-related rises in GH and IGF-1 over 14 days of twice-daily dosing in older men, with the high dose restoring young-adult values [2]. What the studies did not measure is a durable adult body-composition transformation from sermorelin. The clearest body-fat reduction in this research family — a 7.4% drop in percent body fat — came from 20 weeks of the analogue tesamorelin, not from sermorelin [6]. Treat the dramatic before/after framing with that distinction firmly in place. ## Sermorelin, Testosterone and the GH/IGF-1 Axis Sermorelin testosterone questions ask whether the two hormones interact. They do, but through distinct mechanisms. In healthy men aged 60-77, testosterone supplementation itself raised fasting GH and IGF-1 and increased both basal and pulsatile GH secretion — yet it did not change the pituitary's maximal response to GHRH or to GHRP-2 [9]. The reading: testosterone upregulates the GH/IGF-1 axis by multifactorial routes that sit alongside, not inside, the secretagogue pathway. Body fat sits in the same picture. Under a fixed leuprolide/testosterone clamp, abdominal visceral fat was the dominant negative determinant of GHRH-stimulated GH release — about 41% of the variance — while IGF-1 positively predicted GHRP-2 efficacy [8]. A companion study found visceral fat, IGF-1 and IGFBP-3 together explained 60% of the variability in GHRH-GHRP synergy in men [10]. Non-steroidal factors, in other words, strongly govern how much GH a secretagogue can elicit. ## How does sermorelin differ from direct HGH injections? Sermorelin acts upstream on the pituitary to stimulate the body's own pulsatile GH release, leaving somatostatin and IGF-1 feedback intact; recombinant GH supplies the hormone directly and bypasses that regulation. A *Clinical Interventions in Aging* editorial argued that this upstream, feedback-preserving action may make sermorelin a more physiologic approach to adult-onset GH insufficiency [4]. The trade-off is potency and duration: native GHRH(1-29) is short-acting [3]. ## Sermorelin vs Tesamorelin: Native GHRH(1-29) and the Stabilized Analogue Both are GHRH analogues. Sermorelin is native GHRH(1-29); tesamorelin is a stabilized analogue, FDA-approved for HIV-associated lipodystrophy, studied at 1-2 mg/day, where it raised IGF-1 and reduced body fat in controlled trials [6]. In the cognition trial, 1 mg/day for 20 weeks raised IGF-1 by 117% and cut percent body fat by 7.4% [6]. The key reading caveat: tesamorelin findings are drug-class evidence for what a GHRH analogue can do, not sermorelin-specific trial results. ## Sermorelin Side Effects Reported in the Research Literature Across studies, GHRH(1-29) was generally well tolerated, and the most common report is mild, transient injection-site reactions. The off-target signal on record is small and short-term: an acute 1 microgram/kg intravenous dose in 20 short prepubertal children produced small short-term increases in serum prolactin, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), alongside a GH rise comparable to native GHRH 1-40 [7]. Two honest limits frame the safety picture. First, long-term adult safety data — specifically for anti-aging use — are limited [5]. Second, because GH and IGF-1 are mitogenic (they promote cell division), chronically raising them is theorized to carry an oncologic concern; this is a recognized consideration for any GH-axis intervention, even one that works through the body's own feedback-regulated secretion [15]. This is a research summary, not safety advice. ## Does sermorelin affect testosterone? Sermorelin acts on the GH/IGF-1 axis rather than the gonadal axis. In healthy men aged 60-77, testosterone supplementation itself raised GH, IGF-1, and pulsatile GH secretion without changing the pituitary's maximal response to GHRH or GHRP-2, indicating the two axes interact but operate through distinct mechanisms [9]. There is no evidence here that sermorelin directly raises testosterone. ## Sermorelin vs tesamorelin: how do they differ? Both are GHRH analogues acting on the same pituitary receptor. Sermorelin is the native GHRH(1-29) fragment; tesamorelin is a stabilized analogue (FDA-approved for HIV-associated lipodystrophy) studied at 1-2 mg/day, where it raised IGF-1 and reduced body fat in controlled trials [6]. Tesamorelin findings are drug-class evidence for the GHRH axis, not sermorelin-specific trials — a distinction worth keeping when body-composition claims are made for sermorelin. ## What pairs well with sermorelin (e.g., ipamorelin or GHRP-2)? Research has combined GHRH analogues with GHRP-class peptides, which act on the separate ghrelin/GHS receptor. In older adults with low GH/IGF-1, low-dose GHRP-2 augmented the GH response to GHRH(1-44)NH2, and chronic subcutaneous GHRP-2 for 30 days raised pulsatile GH and serum IGF-1 within 24 hours and kept it elevated [11]. This describes studied combinations, not a human dosing recommendation. ## Does sermorelin burn fat? GH-axis stimulation can affect body composition, but visceral fat itself blunts the response: in men, abdominal visceral fat was the dominant negative determinant of GHRH-stimulated GH release, accounting for about 41% of the variance [8]. The strongest visceral-fat-reduction data in this research family come from the related analogue tesamorelin (7.4% reduction in percent body fat), not from sermorelin specifically [6]. ## Is sermorelin effective for weight loss? Sermorelin is not a weight-loss agent. Its GH/IGF-1-axis effects on fat are real but modest and confounded by visceral adiposity, which suppresses GHRH-stimulated GH release [8]. The marketing for weight loss outpaces the rigorous evidence; the clearest body-composition findings involve the analogue tesamorelin [6], and no controlled sermorelin weight-loss trial supports that use. ## Will sermorelin raise my IGF-1 levels? In healthy older men, GHRH(1-29) twice daily for 14 days produced dose-related increases in IGF-1, reversing age-related decreases at the high dose [2]. Because IGF-1 also feeds back to inhibit GH release, the rise stays within a feedback-regulated range rather than climbing without limit [4]. This is a research finding, not a target to dose toward. ## Does sermorelin build muscle? Sermorelin raises GH and IGF-1, hormones central to muscle metabolism [2], but direct controlled evidence of measured muscle-mass gain from sermorelin in healthy adults is limited. Most body-composition data in this family describe IGF-1 changes and the related analogue tesamorelin rather than measured lean-mass increases [6], so a muscle-building claim outruns the sermorelin-specific evidence. ## Does sermorelin affect the brain? GHRH administration has measurable neuroendocrine effects. In a randomized trial in older adults, a GHRH analogue (tesamorelin, 1 mg/day for 20 weeks) had a favorable effect on cognition (executive function P=0.005) and raised IGF-1 by 117% within the physiologic range [6]. This is drug-class evidence for a GHRH effect on the brain, read here as context rather than a sermorelin-specific outcome. ## Can sermorelin or GHRH improve cognition in older adults? A randomized, double-blind, placebo-controlled trial of 152 older adults (including 66 with mild cognitive impairment) found that 20 weeks of a daily GHRH analogue had a favorable effect on cognition (P=0.03), with IGF-1 up 117% and percent body fat down 7.4% [6]. This used the stabilized analogue tesamorelin, framed here as GHRH-axis evidence, not a sermorelin trial. ## How long does it take for sermorelin to work? GH release is rapid — a single intravenous dose elevates serum GH for roughly 3 hours despite the peptide's short half-life [3]. Sustained changes in IGF-1 were measured over 14 days of twice-daily dosing in older men [2]. Durable body-composition or anti-aging effects are not established [5], so "how long" has no settled adult answer beyond these research timelines. ## Does sermorelin actually help with sleep, or is it waking me up instead? GHRH has documented sleep-promoting (slow-wave sleep) effects in normal men, but those effects depend on the time of administration [12] and are reduced in the elderly, paralleling the age-related decline of the GHRH/GH axis [13]. Responses therefore vary with age and timing; the literature does not promise uniform sleep improvement. ## Why is it recommended to inject sermorelin at night? Endogenous GH is secreted in pulses, with the largest pulse during slow-wave sleep; sleep onset and slow-wave sleep are significant for nocturnal GH release [14]. Bedtime dosing in studies leverages that physiologic nocturnal pattern. This describes study protocols and physiology, not a human dosing instruction. ## When is the best time to take sermorelin? Studies favored bedtime administration because slow-wave sleep coincides with the largest nocturnal GH pulse, and sleep onset is significant for nocturnal GH release [14]. The sleep-endocrine effect of GHRH also depends on the time of administration [12]. This reflects study design and physiology, not a recommendation. --- A green-phosphor terminal reading of the sermorelin record — each GHRH(1-29) figure logged to its study, the ~10-12-minute half-life that motivates the longer-acting analogues surfaced first, the formerly-approved-now-compounded history stated as filed, and the body-composition evidence marked as tesamorelin where it belongs; the 'order' here is a command at a prompt, never a checkout, and nothing on this console is dosed, dispensed, or sold.